| A variant associated with nicotine dependence, lung cancer and peripheral arterial disease TE Thorgeirsson, F Geller, P Sulem, T Rafnar, A Wiste, KP Magnusson, ... Nature 452 (7187), 638-642, 2008 | 1686 | 2008 |
| Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... New England Journal of Medicine 387 (1), 9-20, 2022 | 1626 | 2022 |
| Sequence variants at the TERT-CLPTM1L locus associate with many cancer types T Rafnar, P Sulem, SN Stacey, F Geller, J Gudmundsson, A Sigurdsson, ... Nature genetics 41 (2), 221-227, 2009 | 714 | 2009 |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ... NPJ breast cancer 7 (1), 1, 2021 | 454 | 2021 |
| HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer … A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, ... The lancet oncology 18 (4), 545-554, 2017 | 343 | 2017 |
| Frequency and spectrum of PIK3CA somatic mutations in breast cancer O Martínez-Sáez, N Chic, T Pascual, B Adamo, M Vidal, B González-Farré, ... Breast cancer research 22, 1-9, 2020 | 307 | 2020 |
| Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer A Prat, LA Carey, B Adamo, M Vidal, J Tabernero, J Cortés, JS Parker, ... Journal of the National Cancer Institute 106 (8), dju152, 2014 | 267 | 2014 |
| Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer JM Cejalvo, E Martínez de Dueñas, P Galván, S García-Recio, ... Cancer research 77 (9), 2213-2221, 2017 | 263 | 2017 |
| A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ... EMBO molecular medicine 10 (12), e9172, 2018 | 246 | 2018 |
| Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors C Serrano, J Cortés, L De Mattos-Arruda, M Bellet, P Gómez, C Saura, ... Annals of oncology 23 (4), 897-902, 2012 | 214 | 2012 |
| Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy A Prat, C Fan, A Fernández, KA Hoadley, R Martinello, M Vidal, M Viladot, ... BMC medicine 13, 1-11, 2015 | 195 | 2015 |
| HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis F Schettini, T Pascual, B Conte, N Chic, F Brasó-Maristany, P Galván, ... Cancer treatment reviews 84, 101965, 2020 | 141 | 2020 |
| HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ... JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020 | 135 | 2020 |
| Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay A Prat, P Galván, B Jimenez, W Buckingham, HA Jeiranian, C Schaper, ... Clinical Cancer Research 22 (3), 560-566, 2016 | 115 | 2016 |
| Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry A Alegre, J Diaz-Mediavilla, J San-Miguel, R Martinez, JG Laraña, ... Bone marrow transplantation 21 (2), 133-140, 1998 | 110 | 1998 |
| A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual … P Nuciforo, T Pascual, J Cortés, A Llombart-Cussac, R Fasani, L Paré, ... Annals of Oncology 29 (1), 170-177, 2018 | 106 | 2018 |
| Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade F Brasó-Maristany, G Griguolo, T Pascual, L Paré, P Nuciforo, ... Nature communications 11 (1), 385, 2020 | 97 | 2020 |
| Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types L Paré, T Pascual, E Seguí, C Teixidó, M Gonzalez-Cao, P Galván, ... Annals of Oncology 29 (10), 2121-2128, 2018 | 96 | 2018 |
| Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis J Cortes, V Calvo, N Ramírez-Merino, J O'shaughnessy, A Brufsky, ... Annals of oncology 23 (5), 1130-1137, 2012 | 82 | 2012 |
| Symposium review: Decomposing efficiency of milk production and maximizing profit A Bach, M Terré, M Vidal Journal of Dairy Science 103 (6), 5709-5725, 2020 | 77 | 2020 |
